Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis

Arthritis Research and Therapy

Volumn 10, Issue 6, 2008, Pages

  Reddy, Padmalatha S ^a   Legault, Holly M ^a   Sypek, Joseph P ^a   Collins, Mark J ^b   Goad, Elizabeth ^c   Goldman, Samuel J ^a   Liu, Wei ^a   Murray, Stuart ^a   Dorner, Andrew J ^d   O'Toole, Margot ^a  

^a PFIZER INC   (United States)

^b Polysaccharides Quality   (United States)

^c Stryker Orthopaedics   (United States)

^d ajDorner Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DATA BASE; DISEASE MODEL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; KIDNEY PARENCHYMA; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SPECIES COMPARISON; ANIMAL; CHROMOSOME MAP; COMPARATIVE STUDY; GENETICS; MALE; METHODOLOGY; MORTALITY; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NEW ZEALAND BLACK MOUSE; PROTEIN MICROARRAY; SURVIVAL RATE;

ANIMALS; CHROMOSOME MAPPING; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUPUS NEPHRITIS; MALE; MICE; MICE, INBRED MRL LPR; MICE, INBRED NZB; PROTEIN ARRAY ANALYSIS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 57049142569     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2541     Document Type: Article

References (51)

1. Schroder NW Maurer M The role of innate immunity in asthma: Leads and lessons from mouse models Allergy 2007, 62:579-590. 10.1111/ j.1398-9995.2007.01386.x 17508961
2. Sena E Worp van der HB Howells D Macleod M How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 2007, 30:433-439. 10.1016/j.tins.2007.06.009 17765332
3. Sena E Wheble P Sandercock P Macleod M Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke Stroke 2007, 38:388-394. 10.1161/01.STR.0000254462.75851.22 17204689
4. Zosky GR Larcombe AN White OJ Burchell JT Janosi TZ Hantos Z Holt PG Sly PD Turner DJ Ovalbumin-sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation Clin Exp Allergy 2008, 38:829-838. 10.1111/ j.1365-2222.2007.02884.x 18070158
5. Zosky GR Sly PD Animal models of asthma Clin Exp Allergy 2007, 37:973-988. 10.1111/j.1365-2222.2007.02740.x 17581191
6. Bertsias G Ioannidis JP Boletis J Bombardieri S Cervera R Dostal C Font J Gilboe IM Houssiau F Huizinga T Isenberg D Kallenberg CG Khamashta M Piette JC Schneider M Smolen J Sturfelt G Tincani A van Vollenhoven R Gordon C Boumpas DT Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics Ann Rheum Dis 2008, 67:195-205. 10.1136/ard.2007.070367 17504841
7. Rahman A Isenberg DA Systemic lupus erythematosus N Engl J Med 2008, 358:929-939. 10.1056/NEJMra071297 18305268
8. Mason L Berden J Pathogenic factors for the development of lupus nephritis Lupus 2008, 17:251-255. 10.1177/0961203307088250 18372371
9. Boumpas DT Lupus nephritis Nephrol Dial Transplant 2001, 16(Suppl 6):55-57. 11568243
10. Aringer M Smolen JS Cytokine expression in lupus kidneys Lupus 2005, 14:13-18. 10.1191/0961203305lu2053oa 15732282
11. Baudino L Azeredo da Silveira S Nakata M Izui S Molecular and cellular basis for pathogenicity of autoantibodies: Lessons from murine monoclonal autoantibodies Springer Semin Immunopathol 2006, 28:175-184. 10.1007/s00281-006-0037-0 16953439
12. Haas C Ryffel B Le Hir M IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice J Immunol 1997, 158:5484-5491. 9164971
13. Miyake K Nakashima H Akahoshi M Inoue Y Nagano S Tanaka Y Masutani K Hirakata H Gondo H Otsuka T Harada M Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis Rheumatology (Oxford) 2002, 41:518-524. 10.1093/ rheumatology/41.5.518 12011374
14. Santiago-Raber ML Laporte C Reininger L Izui S Genetic basis of murine lupus Autoimmun Rev 2004, 3:33-39. 10.1016/S1568-9972(03)00062-4 14871647
15. Foster MH Relevance of systemic lupus erythematosus nephritis animal models to human disease Semin Nephrol 1999, 19:12-24. 9952277
16. Reilly CM Gilkeson GS Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice Immunol Res 2002, 25:143-153. 10.1385/IR:25:2:143 11999168
17. Liu J Karypis G Hippen KL Vegoe AL Ruiz P Gilkeson GS Behrens TW Genomic view of systemic autoimmunity in MRLlpr mice Genes Immun 2006, 7:156-168. 10.1038/sj.gene.6364286 16508641
18. Shlomchik MJ Craft JE Mamula MJ From T to B and back again: Positive feedback in systemic autoimmune disease Nat Rev Immunol 2001, 1:147-153. 10.1038/35100573 11905822
19. Hutloff A Buchner K Reiter K Baelde HJ Odendahl M Jacobi A Dorner T Kroczek RA Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus Arthritis Rheum 2004, 50:3211-3220. 10.1002/art.20519 15476242
20. Ramos-Barron A Pinera-Haces C Gomez-Alamillo C Santiuste-Torcida I Ruiz JC Buelta-Carrillo L Merino R de Francisco AL Arias M Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment Lupus 2007, 16:775-781. 10.1177/0961203307081401 17895299
21. Warner LM Adams LM Sehgal SN Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus Arthritis Rheum 1994, 37:289-297. 10.1002/art.1780370219 8129783
22. Lui S Yung S Tsang R Zhang F Chan K Tam S Chan T Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice Lupus 2008, 17:305-313. 10.1177/0961203307088289 18413412
23. Chiang GG Abraham RT Targeting the mTOR signaling network in cancer Trends Mol Med 2007, 13:433-442. 10.1016/j.molmed.2007.08.001 17905659
24. Brunet M Campistol JM Diekmann F Guillen D Millan O T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy Mol Diagn Ther 2007, 11:247-256. 17705579
25. Sarbassov DD Ali SM Sabatini DM Growing roles for the mTOR pathway Curr Opin Cell Biol 2005, 17:596-603. 10.1016/j.ceb.2005.09.009 16226444
26. MacDonald AS A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts Transplantation 2001, 71:271-280. 10.1097/00007890-200101270-00019 11213073
27. GEO - Gene Expression Omnibus http://www.ncbi.nlm.nih.gov/geo
28. Reiner A Yekutieli D Benjamini Y Identifying differentially expressed genes using false discovery rate controlling procedures Bioinformatics 2003, 19:368-375. 10.1093/bioinformatics/btf877 12584122
29. Tian L Greenberg SA Kong SW Altschuler J Kohane IS Park PJ Discovering statistically significant pathways in expression profiling studies Proc Natl Acad Sci USA 2005, 102:13544-13549. 1200092 16174746 10.1073/ pnas.0506577102
30. Alperovich G Rama I Lloberas N Franquesa M Poveda R Gomà M Herrero-Fresneda I Cruzado JM Bolaños N Carrera M Grinyó JM Torras J New immunosuppresor strategies in the treatment of murine lupus nephritis Lupus 2007, 16:18-24. 10.1177/0961203306073136 17283580
31. He L Sun Y Takemoto M Norlin J Tryggvason K Samuelsson T Betsholtz C The glomerular transcriptome and a predicted protein-protein interaction network J Am Soc Nephrol 2008, 19:260-268. 10.1681/ASN.2007050588 18032794
32. Peterson KS Huang JF Zhu J D'Agati V Liu X Miller N Erlander MG Jackson MR Winchester RJ Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli J Clin Invest 2004, 113:1722-1733. 420500 15199407
33. Raught B Gingras AC Sonenberg N The target of rapamycin (TOR) proteins Proc Natl Acad Sci USA 2001, 98:7037-7044. 34619 11416184 10.1073/ pnas.121145898
34. Rotig A Munnich A Genetic features of mitochondrial respiratory chain disorders J Am Soc Nephrol 2003, 14:2995-3007. 10.1097/ 01.ASN.0000095481.24091.C9 14638899
35. Berger SP Daha MR Complement in glomerular injury Semin Immunopathol 2007, 29:375-384. 2071951 17901956 10.1007/s00281-007-0090-3
36. Berger SP Daha MR Complement in glomerular nephritis Semin Immunopathol 2007, 29:375-384. 17901956 10.1007/s00281-007-0090-3 2071951
37. Haxhinasto S Mathis D Benoist C The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells J Exp Med 2008, 205:565-574. 2275380 18283119 10.1084/jem.20071477
38. Qu Y Zhang B Zhao L Liu G Ma H Rao E Zeng C Zhao Y The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice Transpl Immunol 2007, 17:153-161. 10.1016/j.trim.2007.01.002 17331841
39. Strauss L Whiteside TL Knights A Bergmann C Knuth A Zippelius A Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin J Immunol 2007, 178:320-329. 17182569
40. Keever-Taylor CA Browning MB Johnson BD Truitt RL Bredeson CN Behn B Tsao A Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis Cytotherapy 2007, 9:144-157. 10.1080/14653240601145223 17453966
41. Kappos L Barkhof F Desmet A The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis; results from a randomized, controlled clinical trial J Neurol 2005, 252(Supplement 2);S46. (abstract) II/46
42. Neuhaus O Kieseier BC Hartung HP Immunosuppressive agents in multiple sclerosis Neurotherapeutics 2007, 4:654-660. 10.1016/j.nurt.2007.08.003 17920546
43. Dowling RJ Zakikhani M Fantus IG Pollak M Sonenberg N Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 2007, 67:10804-10812. 10.1158/ 0008-5472.CAN-07-2310 18006825
44. Penfornis A Kury-Paulin S Immunosuppressive drug-induced diabetes Diabetes Metab 2006, 32:539-546. 17130815
45. Battaglia M Stabilini A Migliavacca B Horejs-Hoeck J Kaupper T Roncarolo MG Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients J Immunol 2006, 177:8338-8347. 17142730
46. Foroncewicz B Mucha K Paczek L Chmura A Rowinski W Efficacy of rapamycin in patient with juvenile rheumatoid arthritis Transpl Int 2005, 18:366-368. 10.1111/j.1432-2277.2004.00070.x 15730500
47. Tsang CK Qi H Liu LF Zheng XF Targeting mammalian target of rapamycin (mTOR) for health and diseases Drug Discov Today 2007, 12:112-124. 10.1016/j.drudis.2006.12.008 17275731
48. Faivre S Kroemer G Raymond E Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 2006, 5:671-688. 10.1038/nrd2062 16883305
49. ClinicalTrial.gov, a service of the National Insitutes of Health http://clinicaltrials.gov
50. Fernandez D Bonilla E Mirza N Niland B Perl A Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus Arthritis Rheum 2006, 54:2983-2988. 10.1002/art.22085 16947529
51. Sirolimus therapy for idopathic and lupus membranous nephropathy http://clinicaltrials.gov/ct2/show/NCT00050713